Redmile Group LLC raised its stake in Oxford Immunotec Global PLC (NASDAQ:OXFD) by 7.5% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,155,949 shares of the company’s stock after acquiring an additional 151,100 shares during the quarter. Oxford Immunotec Global PLC makes up 2.2% of Redmile Group LLC’s portfolio, making the stock its 14th biggest holding. Redmile Group LLC owned approximately 9.34% of Oxford Immunotec Global PLC worth $36,263,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Parkwood LLC raised its holdings in shares of Oxford Immunotec Global PLC by 12.9% in the second quarter. Parkwood LLC now owns 12,799 shares of the company’s stock worth $215,000 after acquiring an additional 1,465 shares during the last quarter. Voya Investment Management LLC raised its holdings in shares of Oxford Immunotec Global PLC by 16.0% in the second quarter. Voya Investment Management LLC now owns 13,345 shares of the company’s stock worth $224,000 after acquiring an additional 1,845 shares during the last quarter. American International Group Inc. raised its holdings in shares of Oxford Immunotec Global PLC by 7.1% in the first quarter. American International Group Inc. now owns 13,668 shares of the company’s stock worth $212,000 after acquiring an additional 904 shares during the last quarter. Nationwide Fund Advisors raised its holdings in shares of Oxford Immunotec Global PLC by 1.9% in the first quarter. Nationwide Fund Advisors now owns 13,765 shares of the company’s stock worth $213,000 after acquiring an additional 254 shares during the last quarter. Finally, Alliancebernstein L.P. acquired a new position in shares of Oxford Immunotec Global PLC in the second quarter worth $247,000. 79.21% of the stock is owned by institutional investors.

Shares of Oxford Immunotec Global PLC (NASDAQ OXFD) traded down 0.59% during midday trading on Friday, hitting $16.77. The stock had a trading volume of 52,235 shares. The firm’s market cap is $386.98 million. The company’s 50-day moving average price is $15.83 and its 200-day moving average price is $15.64. Oxford Immunotec Global PLC has a 12-month low of $11.88 and a 12-month high of $19.51.

Oxford Immunotec Global PLC (NASDAQ:OXFD) last released its earnings results on Tuesday, August 1st. The company reported ($0.32) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.32). The company had revenue of $26.10 million during the quarter, compared to analyst estimates of $25.05 million. Oxford Immunotec Global PLC had a negative return on equity of 35.76% and a negative net margin of 34.58%. The company’s revenue for the quarter was up 35.9% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.29) earnings per share. Equities research analysts forecast that Oxford Immunotec Global PLC will post ($1.61) EPS for the current year.

TRADEMARK VIOLATION WARNING: “Redmile Group LLC Has $36.26 Million Stake in Oxford Immunotec Global PLC (OXFD)” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be read at https://www.thecerbatgem.com/2017/10/08/redmile-group-llc-has-36-26-million-stake-in-oxford-immunotec-global-plc-oxfd.html.

A number of equities analysts have recently weighed in on the company. Cowen and Company cut their price target on Oxford Immunotec Global PLC from $22.00 to $19.00 and set an “outperform” rating for the company in a report on Thursday, August 17th. Zacks Investment Research downgraded Oxford Immunotec Global PLC from a “hold” rating to a “sell” rating in a research report on Saturday, August 5th. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $26.00 price objective on shares of Oxford Immunotec Global PLC in a research report on Thursday, August 3rd. Finally, BTIG Research began coverage on Oxford Immunotec Global PLC in a research report on Thursday, September 28th. They issued a “buy” rating and a $21.00 price objective for the company. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $22.00.

In other news, Director Richard A. Sandberg sold 3,000 shares of the stock in a transaction on Friday, September 1st. The stock was sold at an average price of $15.82, for a total value of $47,460.00. Following the completion of the sale, the director now owns 18,000 shares in the company, valued at $284,760. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Peter Wrighton-Smith sold 55,000 shares of the stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $16.78, for a total value of $922,900.00. The disclosure for this sale can be found here. Insiders sold 90,110 shares of company stock valued at $1,523,514 in the last 90 days. Corporate insiders own 8.11% of the company’s stock.

Oxford Immunotec Global PLC Company Profile

Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.

Want to see what other hedge funds are holding OXFD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Oxford Immunotec Global PLC (NASDAQ:OXFD).

Institutional Ownership by Quarter for Oxford Immunotec Global PLC (NASDAQ:OXFD)

Receive News & Stock Ratings for Oxford Immunotec Global PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global PLC and related stocks with our FREE daily email newsletter.